title: The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival.
abstract: Endometrial carcinomas (ECs) are the most common gynecologic cancers in the western world. The impact of androgen receptor (AR) on clinicopathologic parameters of EC is not well studied. The aim of our study is to assess the role of AR expression in ECs and correlate its expression with estrogen (ER) and progesterone (PR). A retrospective review of 261 EC was conducted. H&E slides were reviewed and clinicopathologic parameters were analyzed. Immunohistochemical stains for AR, ER, and PR were performed on a tissue microarray. The hormonal expression was evaluated and the data were analyzed using the Fisher exact test and Kaplan-Meier survival analysis. Patients' age ranged from 31 to 91 (median=65 y). Type I EC included 202 endometrioid and 7 mucinous carcinoma, whereas type II included 34 serous, 16 carcinosarcoma, and 2 clear cell carcinoma. Although not significant, AR expression showed more frequent association with type I EC, early tumor stage (I-II), and low FIGO grade (1-2) EC. AR expression significantly correlated with absence of lymphovascular invasion (P=0.041) and decreased LN involvement (P=0.048). Patients with AR expression showed increased disease-free survival (208 vs. 165 mo, P=0.008) and late disease recurrence (P=0.009). AR expression had a positive significant correlation with PR (P<0.001) and ER (P=0.037) expression. AR might play a role as a prognostic marker for ECs.
authors.affiliation: Department of Pathology, Detroit Medical Center (Z.M., E.A., V.P., O.H., S.B., R.A.-F.) Departments of Obstetrics and Gynecology (R.M.) Oncology (D.S., M.L.C.), Karmanos Cancer Institute, Wayne State University Henry Ford Hospital (M.A.E.), Detroit, MI.
authors.forename: Zaid
authors.initials: Z
authors.lastname: Mahdi
authors.forename: Eman
authors.initials: E
authors.lastname: Abdulfatah
authors.forename: Vishakha
authors.initials: V
authors.lastname: Pardeshi
authors.forename: Oudai
authors.initials: O
authors.lastname: Hassan
authors.forename: Daniel
authors.initials: D
authors.lastname: Schultz
authors.forename: Robert
authors.initials: R
authors.lastname: Morris
authors.forename: Michele L
authors.initials: ML
authors.lastname: Cote
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Elshaikh
authors.forename: Sudeshna
authors.initials: S
authors.lastname: Bandyopadhyay
authors.forename: Rouba
authors.initials: R
authors.lastname: Ali-Fehmi
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011944:Receptors, Androgen / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: C410798:AR protein, human; D014408:Biomarkers, Tumor; D011944:Receptors, Androgen